Project Grant HT94252410941
Award Date
9/1/24
Completion Date
8/31/28
Dollars Obligated
$4.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
The federal Project Grant award, valued at $1,598,801.00 and awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program, supports a Phase 1B study of the BCL-XL degrader DT2216 combined with paclitaxel in recurrent platinum-resistant ovarian cancer. The study is being conducted by the Dana-Farber Cancer Institute, Inc. (DFCI), a non-profit hospital and cancer research center in Boston, Massachusetts. The award period runs from July 1,...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
The Dana-Farber Cancer Institute, Inc. (DFCI) was awarded a $778,092 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to advance preclinical studies of a dual-targeted fine-tuned immune-restoring (DFIR) CAR-T cell therapy for the treatment of high-grade serous ovarian cancer. The award period is from April 15, 2025 to April 14, 2027. As a leading cancer research institution, DFCI will leverage its expertise in oncology,...
The U.S. Defense Health Agency has awarded a $712,000 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) in Boston, MA. The 2-year grant, with a period of performance from July 1, 2024 to June 30, 2026, will support a longitudinal study to identify mechanisms of treatment resistance in rhabdomyosarcoma through circulating tumor DNA analysis. As a not-for-profit hospital and cancer research...
The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
The Dana-Farber Cancer Institute, Inc. was awarded a $267,000 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to conduct pre-industrial studies of a first-generation dual-targeted, fine-tuned, immune-restoring chimeric antigen receptor T-cell therapy to achieve cures of clear cell renal cell carcinoma. The two-year award period runs from September 30, 2021 through September 30, 2023 and will support...
The Defense Health Agency has awarded a $1,483,340 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (doing business as DFCI) in Boston, MA. The grant, with a performance period from June 1, 2024 to May 31, 2028, will fund research to harness extracellular domain (ECD) cleavage of anaplastic lymphoma kinase (ALK) for immunotherapy against neuroblastoma. As a non-profit hospital and cancer research center, DFCI will...
This $124,230 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research led by Dr. Parikh at the Mayo Clinic in Rochester, Minnesota. The key objectives are to: 1) Complete two ongoing clinical trials evaluating novel combination treatments for untreated chronic lymphocytic leukemia (CLL) patients, including data analysis and manuscript preparation; and 2) Develop the protocol and serve as the national principal investigator for...